<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34613730</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>21</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>02</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1543-8392</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>18</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Nov</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Molecular pharmaceutics</Title>
          <ISOAbbreviation>Mol Pharm</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Impact of Simulated Intestinal Fluids on Dissolution, Solution Chemistry, and Membrane Transport of Amorphous Multidrug Formulations.</ArticleTitle>
        <Pagination>
          <StartPage>4079</StartPage>
          <EndPage>4089</EndPage>
          <MedlinePgn>4079-4089</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.molpharmaceut.1c00480</ELocationID>
        <Abstract>
          <AbstractText>The solution behavior and membrane transport of multidrug formulations were herein investigated in a biorelevant medium simulating fasted conditions. Amorphous multidrug formulations were prepared by the solvent evaporation method. Combinations of atazanavir (ATV) and ritonavir (RTV) and felodipine (FDN) and indapamide (IPM) were prepared and stabilized by a polymer for studying their dissolution (under non-sink conditions) and membrane transport in fasted state simulated intestinal fluid (FaSSIF). The micellar solubilization by FaSSIF enhanced the amorphous solubility of the drugs to different extents. Similar to buffer, the maximum achievable concentration of drugs in combination was reduced in FaSSIF, but the extent of reduction was affected by the degree of FaSSIF solubilization. Dissolution studies of ATV and IPM revealed that the amorphous solubility of these two drugs was not affected by FaSSIF solubilization. In contrast, RTV was significantly affected by FaSSIF solubilization with a 30% reduction in the maximum achievable concentration upon combination to ATV, compared to 50% reduction in buffer. This positive deviation by FaSSIF solubilization was not reflected in the mass transport-time profiles. Interestingly, FDN concentrations remain constant until the amount of IPM added was over 1000 μg/mL. No decrease in the membrane transport of FDN was observed for a 1:1 M ratio of FDN-IPM combination. This study demonstrates the importance of studying amorphous multidrug formulations under physiologically relevant conditions to obtain insights into the performance of these formulations after oral administration.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>El Sayed</LastName>
            <ForeName>Mira</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0003-0314-9065</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Biomedical Centre, Uppsala University, P.O. Box 580, Uppsala SE-751 23, Sweden.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Recipharm OT Chemistry AB, Uppsala SE-754 50, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alhalaweh</LastName>
            <ForeName>Amjad</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Recipharm OT Chemistry AB, Uppsala SE-754 50, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bergström</LastName>
            <ForeName>Christel A S</ForeName>
            <Initials>CAS</Initials>
            <Identifier Source="ORCID">0000-0002-8917-2612</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Biomedical Centre, Uppsala University, P.O. Box 580, Uppsala SE-751 23, Sweden.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Mol Pharm</MedlineTA>
        <NlmUniqueID>101197791</NlmUniqueID>
        <ISSNLinking>1543-8384</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D008567">Membranes, Artificial</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>4MT4VIE29P</RegistryNumber>
          <NameOfSubstance UI="D000069446">Atazanavir Sulfate</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>F089I0511L</RegistryNumber>
          <NameOfSubstance UI="D007190">Indapamide</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>O3J8G9O825</RegistryNumber>
          <NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>OL961R6O2C</RegistryNumber>
          <NameOfSubstance UI="D015736">Felodipine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069446" MajorTopicYN="N">Atazanavir Sulfate</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001826" MajorTopicYN="N">Body Fluids</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002626" MajorTopicYN="N">Chemistry, Pharmaceutical</DescriptorName>
          <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015736" MajorTopicYN="N">Felodipine</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007190" MajorTopicYN="N">Indapamide</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007422" MajorTopicYN="N">Intestines</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008567" MajorTopicYN="N">Membranes, Artificial</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019438" MajorTopicYN="N">Ritonavir</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">FaSSIF</Keyword>
        <Keyword MajorTopicYN="Y">amorphous</Keyword>
        <Keyword MajorTopicYN="Y">fixed dose combination</Keyword>
        <Keyword MajorTopicYN="Y">flux</Keyword>
        <Keyword MajorTopicYN="Y">membrane transport</Keyword>
        <Keyword MajorTopicYN="Y">multidrug formulations</Keyword>
        <Keyword MajorTopicYN="Y">solubility</Keyword>
        <Keyword MajorTopicYN="Y">supersaturation</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no
competing financial interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>6</Day>
          <Hour>17</Hour>
          <Minute>15</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34613730</ArticleId>
        <ArticleId IdType="pmc">PMC8564758</ArticleId>
        <ArticleId IdType="doi">10.1021/acs.molpharmaceut.1c00480</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Webster R.
Fixed-Dose
Combination Medications for Non-Communicable Diseases. Heart
2019, 105, 176–177. 10.1136/heartjnl-2018-313859.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/heartjnl-2018-313859</ArticleId>
            <ArticleId IdType="pubmed">30181197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kikuchi C.; Ohno M.; Izumo T.; Takahashi S.; Aoki M.; Shimomura H.; Kawano Y.; Shimada S.; Aoyama T.
Investigation of Approval
Trends and Benefits of New
Fixed-Dose Combination Drugs in Japan. Ther.
Innov. Regul. Sci.
2020, 54, 200–210. 10.1007/s43441-019-00046-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s43441-019-00046-w</ArticleId>
            <ArticleId IdType="pubmed">32008249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sebaaly J. C.; Kelley D.
HIV Clinical Updates:
New Single-Tablet Regimens. Ann. Pharmacother.
2019, 53, 82–94. 10.1177/1060028018793252.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1060028018793252</ArticleId>
            <ArticleId IdType="pubmed">30073873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishida T.; Oh A.; Hiroi S.; Shimasaki Y.; Nishigaki N.; Tsuchihashi T.
Treatment Patterns and Adherence
to Antihypertensive
Combination Therapies in Japan Using a Claims Database. Hypertens. Res.
2019, 42, 249–256. 10.1038/s41440-018-0127-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41440-018-0127-0</ArticleId>
            <ArticleId IdType="pmc">PMC8075995</ArticleId>
            <ArticleId IdType="pubmed">30443023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yilancioglu K.; Cokol M.
Design of High-Order
Antibiotic Combinations against M. Tuberculosis
by Ranking and Exclusion. Sci. Rep.
2019, 9, 11876.10.1038/s41598-019-48410-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41598-019-48410-y</ArticleId>
            <ArticleId IdType="pmc">PMC6695482</ArticleId>
            <ArticleId IdType="pubmed">31417151</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>World Health Organization . World Health Organization Model List of
Essential Medicines, 21st List, 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>Kavanagh O. N.; Albadarin A. B.; Croker D. M.; Healy A. M.; Walker G. M.
Maximising
Success in Multidrug Formulation Development: A Review. J. Controlled Release
2018, 283, 1–19. 10.1016/j.jconrel.2018.05.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jconrel.2018.05.024</ArticleId>
            <ArticleId IdType="pubmed">29802867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trasi N. S.; Bhujbal S.; Zhou Q. T.; Taylor L. S.
Amorphous solid
dispersion formation via solvent granulation - A case study with ritonavir
and lopinavir. Int. J. Pharm. X
2019, 1, 100035.10.1016/j.ijpx.2019.100035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijpx.2019.100035</ArticleId>
            <ArticleId IdType="pmc">PMC6880113</ArticleId>
            <ArticleId IdType="pubmed">31788669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laitinen R.; Löbmann K.; Grohganz H.; Priemel P.; Strachan C. J.; Rades T.
Supersaturating Drug Delivery Systems:
The Potential of Co-Amorphous
Drug Formulations. Int. J. Pharm.
2017, 532, 1–12. 10.1016/j.ijpharm.2017.08.123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2017.08.123</ArticleId>
            <ArticleId IdType="pubmed">28870764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen D. N.; Van Den Mooter G.
The Fate of Ritonavir in the Presence
of Darunavir. Int. J. Pharm.
2014, 475, 214–226. 10.1016/j.ijpharm.2014.08.062.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2014.08.062</ArticleId>
            <ArticleId IdType="pubmed">25180992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trasi N. S.; Taylor L. S.
Dissolution performance of binary
amorphous drug combinations-Impact
of a second drug on the maximum achievable supersaturation. Int. J. Pharm.
2015, 496, 282–290. 10.1016/j.ijpharm.2015.10.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2015.10.026</ArticleId>
            <ArticleId IdType="pubmed">26456250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alhalaweh A.; Bergström C. A. S.; Taylor L. S.
Compromised in Vitro
Dissolution and Membrane Transport of Multidrug Amorphous Formulations. J. Controlled Release
2016, 229, 172–182. 10.1016/j.jconrel.2016.03.028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jconrel.2016.03.028</ArticleId>
            <ArticleId IdType="pubmed">27006280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trasi N. S.; Taylor L. S.
Thermodynamics of
Highly Supersaturated Aqueous Solutions
of Poorly Water-Soluble Drugs-Impact of a Second Drug on the Solution
Phase Behavior and Implications for Combination Products. J. Pharm. Sci.
2015, 104, 2583–2593. 10.1002/jps.24528.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jps.24528</ArticleId>
            <ArticleId IdType="pubmed">26059413</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El
Sayed M.; Alhalaweh A.; Bergström C. A. S.
Insights
into Dissolution and Solution Chemistry of Multidrug Formulations
of Antihypertensive Drugs. Mol. Pharm.
2020, 17, 4018–4028. 10.1021/acs.molpharmaceut.0c00835.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.molpharmaceut.0c00835</ArticleId>
            <ArticleId IdType="pubmed">32870692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ueda K.; Taylor L. S.
Partitioning of
Surfactant into Drug-Rich Nanodroplets
and Its Impact on Drug Thermodynamic Activity and Droplet Size. J. Controlled Release
2021, 330, 229–243. 10.1016/j.jconrel.2020.12.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jconrel.2020.12.018</ArticleId>
            <ArticleId IdType="pubmed">33340567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stewart A. M.; Grass M. E.; Mudie D. M.; Morgen M. M.; Friesen D. T.; Vodak D. T.
Development of a
Biorelevant, Material-Sparing Membrane
Flux Test for Rapid Screening of Bioavailability-Enhancing Drug Product
Formulations. Mol. Pharm.
2017, 14, 2032–2046. 10.1021/acs.molpharmaceut.7b00121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.molpharmaceut.7b00121</ArticleId>
            <ArticleId IdType="pubmed">28441497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stewart A. M.; Grass M. E.
Practical Approach
to Modeling the Impact of Amorphous
Drug Nanoparticles on the Oral Absorption of Poorly Soluble Drugs. Mol. Pharm.
2020, 17, 180–189. 10.1021/acs.molpharmaceut.9b00889.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.molpharmaceut.9b00889</ArticleId>
            <ArticleId IdType="pubmed">31743032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kesisoglou F.; Wang M.; Galipeau K.; Harmon P.; Okoh G.; Xu W.
Effect of Amorphous
Nanoparticle Size on Bioavailability of Anacetrapib
in Dogs. J. Pharm. Sci.
2019, 108, 2917–2925. 10.1016/j.xphs.2019.04.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.xphs.2019.04.006</ArticleId>
            <ArticleId IdType="pubmed">30980857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Newman A.; Knipp G.; Zografi G.
Assessing the Performance
of Amorphous
Solid Dispersions. J. Pharm. Sci.
2012, 101, 1355–1377. 10.1002/jps.23031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jps.23031</ArticleId>
            <ArticleId IdType="pubmed">22213468</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Edueng K.; Mahlin D.; Larsson P.; Bergström C. A. S.
Mechanism-based
selection of stabilization strategy for amorphous formulations: Insights
into crystallization pathways. J. Controlled
Release
2017, 256, 193–202. 10.1016/j.jconrel.2017.04.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jconrel.2017.04.015</ArticleId>
            <ArticleId IdType="pmc">PMC5488750</ArticleId>
            <ArticleId IdType="pubmed">28412224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Almeida
E Sousa L.; Reutzel-Edens S. M.; Stephenson G. A.; Taylor L. S.
Supersaturation Potential of Salt, Co-Crystal, and
Amorphous Forms of a Model Weak Base. Cryst.
Growth Des.
2016, 16, 737–748. 10.1021/acs.cgd.5b01341.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.cgd.5b01341</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ilevbare G. A.; Taylor L. S.
Liquid-Liquid Phase
Separation in Highly Supersaturated
Aqueous Solutions of Poorly Water-Soluble Drugs: Implications for
Solubility Enhancing Formulations. Cryst. Growth
Des.
2013, 13, 1497–1509. 10.1021/cg301679h.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/cg301679h</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ueda K.; Hate S. S.; Taylor L. S.
Impact
of Hypromellose Acetate Succinate
Grade on Drug Amorphous Solubility and In Vitro Membrane Transport. J. Pharm. Sci.
2020, 109, 2464–2473. 10.1016/j.xphs.2020.04.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.xphs.2020.04.014</ArticleId>
            <ArticleId IdType="pubmed">32353454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ueda K.; Taylor L. S.
Polymer Type Impacts Amorphous Solubility and Drug-Rich
Phase Colloidal Stability: A Mechanistic Study Using Nuclear Magnetic
Resonance Spectroscopy. Mol. Pharm.
2020, 17, 1352–1362. 10.1021/acs.molpharmaceut.0c00061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.molpharmaceut.0c00061</ArticleId>
            <ArticleId IdType="pubmed">32097023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hate S. S.; Reutzel-Edens S. M.; Taylor L. S.
Insight into Amorphous Solid Dispersion
Performance by Coupled Dissolution and Membrane Mass Transfer Measurements. Mol. Pharm.
2019, 16, 448–461. 10.1021/acs.molpharmaceut.8b01117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.molpharmaceut.8b01117</ArticleId>
            <ArticleId IdType="pubmed">30521350</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson V.; Lou X.; Osterling D. J.; Stolarik D. F.; Jenkins G.; Gao W.; Zhang G. G. Z.; Taylor L. S.
Relationship between Amorphous Solid
Dispersion In Vivo Absorption and In Vitro Dissolution: Phase Behavior
during Dissolution, Speciation, and Membrane Mass Transport. J. Controlled Release
2018, 292, 172–182. 10.1016/j.jconrel.2018.11.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jconrel.2018.11.003</ArticleId>
            <ArticleId IdType="pubmed">30408553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elkhabaz A.; Moseson D. E.; Brouwers J.; Augustijns P.; Taylor L. S.
Interplay of Supersaturation and
Solubilization: Lack
of Correlation between Concentration-Based Supersaturation Measurements
and Membrane Transport Rates in Simulated and Aspirated Human Fluids. Mol. Pharm.
2019, 16, 5042–5053. 10.1021/acs.molpharmaceut.9b00956.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.molpharmaceut.9b00956</ArticleId>
            <ArticleId IdType="pubmed">31638397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Indulkar A. S.; Mo H.; Gao Y.; Raina S. A.; Zhang G. G. Z.; Taylor L. S.
Impact
of Micellar Surfactant on Supersaturation and Insight into Solubilization
Mechanisms in Supersaturated Solutions of Atazanavir. Pharm. Res.
2017, 34, 1276–1295. 10.1007/s11095-017-2144-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11095-017-2144-0</ArticleId>
            <ArticleId IdType="pubmed">28352994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fagerberg J. H.; Tsinman O.; Sun N.; Tsinman K.; Avdeef A.; Bergström C. A. S.
Dissolution
Rate and Apparent Solubility
of Poorly Soluble Drugs in Biorelevant Dissolution Media. Mol. Pharm.
2010, 7, 1419–1430. 10.1021/mp100049m.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/mp100049m</ArticleId>
            <ArticleId IdType="pubmed">20507160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dunn C.; Perrier J.; Khadra I.; Wilson C. G.; Halbert G. W.
Topography
of Simulated Intestinal Equilibrium Solubility. Mol. Pharm.
2019, 16, 1890–1905. 10.1021/acs.molpharmaceut.8b01238.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.molpharmaceut.8b01238</ArticleId>
            <ArticleId IdType="pmc">PMC6505523</ArticleId>
            <ArticleId IdType="pubmed">30848917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Auch C.; Jede C.; Harms M.; Wagner C.; Mäder K.
Impact of
Amorphization and GI Physiology on Supersaturation and Precipitation
of Poorly Soluble Weakly Basic Drugs Using a Small-Scale in Vitro
Transfer Model. Int. J. Pharm.
2020, 574, 118917.10.1016/j.ijpharm.2019.118917.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijpharm.2019.118917</ArticleId>
            <ArticleId IdType="pubmed">31811926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kleberg K.; Jacobsen J.; Müllertz A.
Characterising
the Behaviour of Poorly
Water Soluble Drugs in the Intestine: Application of Biorelevant Media
for Solubility, Dissolution and Transport Studies. J. Pharm. Pharmacol.
2010, 62, 1656–1668. 10.1111/j.2042-7158.2010.01023.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.2042-7158.2010.01023.x</ArticleId>
            <ArticleId IdType="pubmed">21039549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Indulkar A. S.; Gao Y.; Raina S. A.; Zhang G. G. Z.; Taylor L. S.
Crystallization
from Supersaturated Solutions: Role of Lecithin and Composite Simulated
Intestinal Fluid. Pharm. Res.
2018, 35, 158.10.1007/s11095-018-2441-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11095-018-2441-2</ArticleId>
            <ArticleId IdType="pubmed">29916053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Achenbach C. J.; Darin K. M.; Murphy R. L.; Katlama C.
Atazanavir/Ritonavir-Based
Combination Antiretroviral Therapy for Treatment of HIV-1 Infection
in Adults. Futur. Virol.
2011, 6, 157–177. 10.2217/fvl.10.89.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/fvl.10.89</ArticleId>
            <ArticleId IdType="pmc">PMC3127229</ArticleId>
            <ArticleId IdType="pubmed">21731578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alzghoul A.; Alhalaweh A.; Mahlin D.; Bergström C. A. S.
Experimental
and Computational Prediction of Glass Transition Temperature of Drugs. J. Chem. Inf. Model.
2014, 54, 3396–3403. 10.1021/ci5004834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/ci5004834</ArticleId>
            <ArticleId IdType="pubmed">25361075</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arca H. Ç.; Mosquera-Giraldo L. I.; Dahal D.; Taylor L. S.; Edgar K. J.
Multidrug, Anti-HIV
Amorphous Solid Dispersions: Nature
and Mechanisms of Impacts of Drugs on Each Other’s Solution
Concentrations. Mol. Pharm.
2017, 14, 3617–3627. 10.1021/acs.molpharmaceut.7b00203.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.molpharmaceut.7b00203</ArticleId>
            <ArticleId IdType="pubmed">28872867</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li N.; Taylor L. S.
Tailoring Supersaturation
from Amorphous Solid Dispersions. J. Controlled
Release
2018, 279, 114–125. 10.1016/j.jconrel.2018.04.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jconrel.2018.04.014</ArticleId>
            <ArticleId IdType="pmc">PMC5972073</ArticleId>
            <ArticleId IdType="pubmed">29654798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang S.; Mao C.; Williams R. O.; Yang C.-Y.
Solubility Advantage (and Disadvantage)
of Pharmaceutical Amorphous Solid Dispersions. J. Pharm. Sci.
2016, 105, 3549–3561. 10.1016/j.xphs.2016.08.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.xphs.2016.08.017</ArticleId>
            <ArticleId IdType="pubmed">27692620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyako Y.; Tai H.; Ikeda K.; Kume R.; Pinal R.
Solubility Screening
on a Series of Structurally Related Compounds: Cosolvent-Induced Changes
on the Activity Coefficient of Hydrophobic Solutes. Drug Dev. Ind. Pharm.
2008, 34, 499.10.1080/03639040701744020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/03639040701744020</ArticleId>
            <ArticleId IdType="pubmed">18473232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pinal R.; Yalkowsky S. H.
Solubility
and Partitioning I: Solubility of Nonelectrolytes
in Water. J. Pharm. Sci.
1988, 77, 518–522. 10.1002/jps.2600770611.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jps.2600770611</ArticleId>
            <ArticleId IdType="pubmed">3171932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyako Y.; Tai H.; Ikeda K.; Kume R.; Pinal R.
Solubility Screening
on a Series of Structurally Related Compounds: Cosolvent-Induced Changes
on the Activity Coefficient of Hydrophobic Solutes. Drug Dev. Ind. Pharm.
2008, 34, 499–505. 10.1080/03639040701744020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/03639040701744020</ArticleId>
            <ArticleId IdType="pubmed">18473232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He Y.; Tabibi S. E.; Yalkowsky S. H.
Solubilization
of Two Structurally
Related Anticancer Drugs: XK-469 and PPA. J.
Pharm. Sci.
2006, 95, 97–107. 10.1002/jps.20500.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jps.20500</ArticleId>
            <ArticleId IdType="pubmed">16315229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davis A. F.; Hadgraft J.
Effect of Supersaturation
on Membrane Transport: 1.
Hydrocortisone Acetate. Int. J. Pharm.
1991, 76, 1–8. 10.1016/0378-5173(91)90337-n.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0378-5173(91)90337-n</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mosquera-Giraldo L. I.; Taylor L. S.
Glass-Liquid Phase
Separation in Highly Supersaturated
Aqueous Solutions of Telaprevir. Mol. Pharm.
2015, 12, 496–503. 10.1021/mp500573z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/mp500573z</ArticleId>
            <ArticleId IdType="pubmed">25541813</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
